Seeking Alpha

Allergan (AGN) reports a successful Phase III trial of its treatment for overactive bladders....

Allergan (AGN) reports a successful Phase III trial of its treatment for overactive bladders. The company says that based on the results it has pushed forward with applications to the FDA and EU to expand the range of patients approved for the medication.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector